Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma

FDA accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma

Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment

Henlius’ HLX43 in combination with Serplulimab phase 2 NSCLC trial approved in Australia

Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first...

Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers